Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Janssen Files Tremfya for Ulcerative Colitis in Japan
Janssen Pharmaceutical said on April 25 that it has filed its human anti-IL-23 monoclonal antibody Tremfya (guselkumab) in Japan for the treatment of adults with moderately to severely active ulcerative colitis inadequately controlled with existing therapies. The drug is already…
To read the full story
Related Article
- Takeda’s Livmarli, BMS’s Camzyos, and More Inch Closer to Japan Approval
March 7, 2025
- J&J Files Tremfya SC Induction Regimen for UC in Japan
March 7, 2025
- Takeda’s Livmarli, BMS’s Camzyos and More Up for MHLW Panel Review on March 6
February 21, 2025
- Tremfya Filed for Crohn’s Disease in Japan: J&J
August 13, 2024
BUSINESS
- Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
- Mochida Seeks Pediatric Expansion for Urece
July 2, 2026
- Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
- GNI Closes Acquisition of Ayumi Pharma
July 2, 2026
- Toho to Acquire Ishin Pharma, Bring Allostem Distribution In-House
July 2, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…